Cognition Therapeutics (CGTX) Expected to Announce Earnings on Wednesday

Cognition Therapeutics (NASDAQ:CGTX) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Cognition Therapeutics to post earnings of ($0.06) per share and revenue of $4.40 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. On average, analysts expect Cognition Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cognition Therapeutics Price Performance

CGTX opened at $1.28 on Tuesday. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The company has a fifty day simple moving average of $1.05 and a 200 day simple moving average of $1.33. The stock has a market cap of $114.37 million, a P/E ratio of -3.88 and a beta of 1.81.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CGTX. Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of Cognition Therapeutics in a research report on Friday, March 27th. upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Friday, March 27th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cognition Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $3.33.

Hedge Funds Weigh In On Cognition Therapeutics

A number of large investors have recently added to or reduced their stakes in CGTX. Vanguard Group Inc. increased its holdings in Cognition Therapeutics by 105.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock worth $3,620,000 after purchasing an additional 1,377,263 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Cognition Therapeutics by 814.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after purchasing an additional 897,353 shares in the last quarter. Millennium Management LLC bought a new position in Cognition Therapeutics during the 3rd quarter worth about $757,000. Renaissance Technologies LLC increased its holdings in Cognition Therapeutics by 35.9% during the 4th quarter. Renaissance Technologies LLC now owns 969,513 shares of the company’s stock worth $1,309,000 after purchasing an additional 256,013 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Cognition Therapeutics by 22.6% during the 4th quarter. Geode Capital Management LLC now owns 873,954 shares of the company’s stock worth $1,180,000 after purchasing an additional 161,227 shares in the last quarter. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.